In Vivo CAR-T Therapies-A New Era of Programmable Immunity

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Ex vivo CAR-T cell therapy has shown success in treating hematologic malignancies but faces manufacturing and cost limitations.
• Reduced biotech investment since 2022 has further highlighted the need for more accessible cell therapies.
• In vivo CAR-T approaches aim to generate CAR-T cells within the patient, addressing ex vivo limitations.

Purpose of the Study:

• To review major and emerging in vivo CAR-T delivery platforms.
• To analyze the technology, performance, and developmental paths of these platforms.
• To discuss the scientific, technical, and biological challenges in the field.

Main Methods:

• Review of existing literature on in vivo CAR-T delivery systems.
• Analysis of preclinical and clinical data for various delivery platforms (lentiviral, LNPs).
• Discussion of safety, efficacy, and regulatory considerations.

Main Results:

• In vivo CAR-T strategies using lentiviral or lipid nanoparticle (LNP) vectors show potential for streamlined production and reduced costs.
• These approaches raise new challenges concerning genomic safety, immune response, and regulatory oversight.
• The field is rapidly evolving with ongoing research into programmable T cell immunity.

Conclusions:

• In vivo CAR-T cell generation presents a significant advancement with the potential to broaden access to CAR-T therapies.
• Addressing safety, specificity, and regulatory hurdles is crucial for clinical translation.
• Further research into delivery platforms and biological challenges will shape the future of in vivo CAR-T therapy.